Digestive and Liver Diseases

Overview

The Digestive & Liver Diseases research area is composed by three groups, whose main goal is to develop basic and traslational studies on the most frequent and impacting digestive and liver disorders afflicting the general population. In particular, the group of Physiology and Pathophysiology of the Digestive Tract integrates investigations on the function of the gastrointestinal tract including secretion, motility and absorption with cellular, molecular, immune and genetic aspects and their interactions with the microbiota and the brain-gut axis. The Liver Diseases Group deals clinical and basic research in viral hepatitis, liver cirrhosis, liver cancer and also non-alcoholic fatty liver disease and their complications. Finally, our area includes the Multidisciplinar Nursing research group which aims to generate knowledge in the specific area of activity of nurses and collaborate with other health professionals to improve care given to patients.

Publications

102

total

584.988

impact factor

5.735

average impact factor

Group Leader: Joan Genescà Ferrer

team

group-zoom

zoom

group-download

download

During 2018, we have continued our internationalization in terms of grants, publications, participation in different consortia, and most importantly our involvement in the design of clinical guidelines for liver diseases in Europe and involvement in European Institutions for Liver Diseases.

63

total

396^.080

impact factor

6^.287

average impact factor

SELECTED ARTICLES

MIDODRINE &ALBUMIN for Preventing COMPLICATIONS IN PATIENTS WITH CIRRHOSIS AWAITING Liver transplantation. Sola E, Sole C, Simon-Talero M, Martin-Llahi M, Castellote J, Garcia-Martinez R, Moreira R, Torrens M, Marquez F, Fabrellas N, Prada G, Huelin P, Benaiges EL, Ventura M, Manriquez M, Nazar A, Ariza X, Sune P, Graupera I, Pose E, Colmenero J, Pavesi M, Guevara M, Navasa M, Xiol X, Cordoba J, Vargas V, Gines P
J Hepatol. 2018 Dec;69(6):1250-1259.
doi: 10.1016/j.jhep.2018.08.006. Epub 2018 Aug 21.
Impact factor: 14,911
Resistance of high fitness hepatitis C virus to lethal mutagenesis. Gallego I, Gregori J, Soria ME, Garcia-Crespo C, Garcia-Alvarez M, Gomez-Gonzalez A, Valiergue R, Gomez J, Esteban JI, Quer J, Domingo E, Perales C
Virology. 2018 Oct;523:100-109.
doi: 10.1016/j.virol.2018.07.030. Epub 2018 Aug 11.
Impact factor: 3,374
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With HCV genotype 3 Infection and Cirrhosis.
Esteban R, Pineda JA, Calleja JL, Casado M, Rodriguez M, Turnes J, Morano Amado LE, Morillas RM, Forns X, Pascasio Acevedo JM, Andrade RJ, Rivero A, Carrion JA, Lens S, Riveiro-Barciela M, McNabb B, Zhang G, Camus G, Stamm LM, Brainard DM, Subramanian GM, Buti M
Gastroenterology. 2018 Oct;155(4):1120-1127.e4.
doi: 10.1053/j.gastro.2018.06.042. Epub 2018 Jun 27.
Impact factor: 20,773
Restoration of A Healthy Intestinal Microbiota Normalizes Portal Hypertension In A Rat Model of Nonalcoholic Steatohepatitis.
Garcia-Lezana T, Raurell I, Bravo M, Torres-Arauz M, Salcedo MT, Santiago A, Schoenenberger A, Manichanh C, Genesca J, Martell M, Augustin S
Hepatology. 2018 Apr;67(4):1485-1498.
doi: 10.1002/hep.29646. Epub 2018 Feb 19.
Impact factor: 14,079
Decompensated liver disease due to primary hepatic amyloidosis: Is liver transplantation still mandatory?
Riveiro-Barciela M, Gironella M, Senin A, Salcedo MT, Merino-Casabiel X, Castells L, Esteban R, Buti M, Martinez-Valle F
Hepatology. 2018 Dec 18.
doi: 10.1002/hep.30464.
Impact factor: 14,079

View all publications